2022

Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine

Sanofi and Innate Pharma: Expanding Oncology Collaboration

Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis

Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis

Press Release: Statement from Sanofi regarding Horizon Therapeutics plc (“Horizon”)

Media Update: Sanofi to showcase new data from oncology portfolio spanning marketed products and investigational compounds at ASH 2022

Media Update: Sanofi to present new clinical data reinforcing novel therapies across rare blood disorders at ASH 2022

Acoziborole: Sanofi raises hope for elimination of sleeping sickness in Africa

Sanofi moves into its new Paris global headquarters

Press Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease

Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis

Press Release: Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission

Beyfortus® (nirsevimab) granted first worldwide approval for the prevention of RSV disease

Press Release: Continued strong growth in Q3 with key regulatory milestones achieved

Media Update: New two-year efficacy and safety data for tolebrutinib, Sanofi’s investigational, brain-penetrant and bioactive BTK inhibitor, to be presented at ECTRIMS 2022

Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old

Dupixent® (dupilumab) Now an FDA Approved Drug for Prurigo Nodularis Treatment

Press Release: Availability of the Q3 2022 Memorandum for modelling purposes

Media Update: CHMP recommends approval of Enjaymo™ (sutimlimab), first and only approved treatment for hemolytic anemia in adult patients with cold agglutinin disease

A Significant Step Forward for Beyfortus® (nirsevimab), Sanofi's RSV Vaccine

Media Update: Positive Dupixent® (dupilumab) Phase 3 data in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis published in The Lancet

Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis

Media Update: New Dupixent® (dupilumab) data at EADV 2022 adds to body of evidence across multiple inflammatory skin diseases

Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma

Press Release: Evolution of the Board of Directors

Press Release: XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)

Press Release: FDA grants priority review to efanesoctocog alfa for people with hemophilia A

Media Update: New Dupixent® (dupilumab) data at ERS adds to body of safety and efficacy data in chronic respiratory diseases

Press Release: Sanofi provides update on amcenestrant clinical development program

Sanofi Media Update

Insights into Sanofi's Tolebrutinib Clinical Trials Progress

Innovent-Sanofi Collaboration: Elevating Biologic Research

Press Release: Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease

Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis

Press Release: Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis

Press Release: Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis

Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries

FDA holds clinical trial enrollment for Tolebrutinib Phase 3 Studies

Press Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD

Press Release: Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease

Availability of the Q2 2022 Memorandum for modelling purposes

Sanofi-GSK Reports Successful Efficacy Study Against Omicron with COVID-19 Beta-containing Vaccine

Media Update: Survey: Physicians and pharmacists would tell CDC to recommend vaccine like Fluzone High-Dose Quadrivalent (Influenza Vaccine) for people 65 years and older

Sanofi-GSK's Next-Generation COVID-19 Booster: An Advanced Shield Against Emerging Variants

Media Update: Sanofi, a leader in immune-mediated rare blood disorders, to present latest data at EHA 2022

Sanofi Launches Digital Accelerator: Pioneering Healthcare Innovation

Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis

Sanofi Launches Worldwide Employee Share Ownership Plan for 2022

Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab)

FDA Grants Breakthrough Therapy Designation to Efanesoctocog Alfa

Press Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis

Update on Cialis® Rx-to-OTC Switch Actual Use Trial

Dupixent® (dupilumab): the First & Only FDA-approved Medicine for Eosinophilic Esophagitis

Media Update: CHMP recommends approval of Xenpozyme® (olipudase alfa), the first and only treatment for ASMD

Media Update: New data from fast-growing innovative Oncology pipeline and portfolio to be presented at 2022 ASCO Annual Meeting

Press Release: Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy

Transforming Pediatric Health: Sanofi's Nirsevimab in the Fight Against RSV

Press Release: Foundation S: Sanofi’s new philanthropic spearhead

Press Release: Annual General Meeting of May 3, 2022

Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1

Press Release: Sanofi teams up with McLaren Racing to accelerate industrial excellence

Media Update: Rezurock® (belumosudil) patient-reported outcomes correlated with clinical response in chronic graft-versus-host disease

Press Release: Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine

Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation

Press Release: Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board

Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis

Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022

Press Release: Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines

Press Release: Availability of the Q1 2022 Memorandum for modelling purposes

Breaking Boundaries in Healthcare: Sanofi & IGM Biosciences Collaboration

Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver

Press Release: Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency

Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis

Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris

Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates

Sanofi & Blackstone Collaboration for Sarclisa® (isatuximab) Advancement in treating Multiple Myeloma

Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer

Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment

Sanofi recognized by S&P as one of the most sustainability-committed companies

Nirsevimab Shows 74.5% Reduction in RSV Infections in Phase 3 Trial

Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis

Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria

New preclinical tolebrutinib data demonstrated superior brain penetration and potency

Filing of the 2021 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine

Sanofi’s Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors

Latest Updates on Dupixent® (dupilumab) Chronic Spontaneous Urticaria Clinical Trials

Nirsevimab EMA regulatory submission accepted under accelerated assessment for RSV protection in all infants

FDA accepts Dupixent® (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis

Olipudase alfa shown to provide sustained improvement across multiple clinical manifestations of ASMD

Nexviazyme® (avalglucosidase alfa) shows sustained improvements in respiratory function and mobility in patients with Pompe disease

Sanofi completes acquisition of Amunix

FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease

Press Release: Strong 2021 sales and business EPS growth enabling increased investment in R&D

Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity

Positive Dupixent® (dupilumab) data across five diseases with underlying type 2 inflammation to be presented at 2022 AAAAI Annual Meeting

CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation

Sanofi and Regeneron provide regulatory update on Libtayo® (cemiplimab-rwlc) in advanced cervical cancer

Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis

Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines

Availability of the Q4 2021 Memorandum for modelling purposes